Role of circulating tumor cell clusters in patients with metastatic hormone-sensitive prostate cancer receiving a gonadotropin-releasing hormone antagonist: A pilot study
aDivision of Urology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan bDepartment of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan cNihon Gene Research Laboratories Inc, Sendai, Japan dDivision of Pathology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
. [J]. Asian Journal of Urology, 2023, 10(2): 210-212.
Yuki Kohada,Hiroki Kusumoto,Takashi Kukimoto,Jotaro Mikami,Jun Ito,Katsutoshi Asano,Toru Yaegashi,Kanichi Nakagawara,Jun Teishima,Yasuhiro Kaiho,Nobuyuki Hinata,Yasuhiro Nakamura,Makoto Sato. Role of circulating tumor cell clusters in patients with metastatic hormone-sensitive prostate cancer receiving a gonadotropin-releasing hormone antagonist: A pilot study. Asian Journal of Urology, 2023, 10(2): 210-212.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30.
doi: 10.3322/caac.21332
[2]
Kita Y, Goto T, Akamatsu S, Yamasaki T, Inoue T, Ogawa O, et al. Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: opportunities and challenges. Cancers 2018; 10:345. https://doi.org/10.3390/cancers10100345.
doi: 10.3390/cancers10100345
[3]
Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, Farace F. CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs). Cells 2019; 8:1145. https://doi.org/10.3390/cells8101145.
doi: 10.3390/cells8101145
[4]
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-9.
doi: 10.1158/1078-0432.CCR-08-0872
pmid: 18829513
[5]
Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10:233-9.
doi: 10.1016/S1470-2045(08)70340-1
pmid: 19213602
[6]
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158:1110-22.
doi: S0092-8674(14)00927-1
pmid: 25171411
[7]
Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Prostate 2018; 78:576-82.
doi: 10.1002/pros.23501
pmid: 29508425
[8]
Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101:61-6.
doi: 10.1093/jnci/djn419
pmid: 19116383
[9]
Gogoi P, Sepehri S, Zhou Y, Gorin MA, Paolillo C, Capoluongo E, et al. Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples. PLoS One 2016; 11:e0147400. https://doi.org/10.1371/jour-nal.pone.0147400.
doi: 10.1371/journal.pone.0147400
[10]
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016; 34:1402-19.
doi: 10.1200/JCO.2015.64.2702
pmid: 26903579
